HC Wainwright Has Optimistic Outlook of TNGX Q2 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 earnings estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, June 30th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.35) per share for the quarter, up from their previous estimate of ($0.37). HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Tango Therapeutics' Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.45) EPS, Q2 2026 earnings at ($0.40) EPS and Q4 2026 earnings at ($0.37) EPS.

Tango Therapeutics Price Performance

Shares of TNGX stock traded up $0.04 during trading hours on Wednesday, hitting $5.69. The stock had a trading volume of 620,177 shares, compared to its average volume of 1,585,611. The stock's 50 day moving average is $3.16 and its 200 day moving average is $2.59. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $12.02. The firm has a market capitalization of $616.74 million, a PE ratio of -4.66 and a beta of 1.63.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). The firm had revenue of $5.39 million for the quarter, compared to analysts' expectations of $6.73 million. Tango Therapeutics had a negative return on equity of 62.75% and a negative net margin of 322.67%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. TCG Crossover Management LLC acquired a new position in shares of Tango Therapeutics during the 4th quarter valued at about $33,174,000. Boxer Capital Management LLC purchased a new stake in shares of Tango Therapeutics during the fourth quarter worth about $32,077,000. Gilead Sciences Inc. purchased a new stake in shares of Tango Therapeutics during the fourth quarter worth about $15,000,000. Farallon Capital Management LLC acquired a new position in Tango Therapeutics in the fourth quarter worth about $12,360,000. Finally, Balyasny Asset Management L.P. grew its stake in Tango Therapeutics by 22.0% in the fourth quarter. Balyasny Asset Management L.P. now owns 3,279,196 shares of the company's stock worth $10,133,000 after purchasing an additional 592,000 shares in the last quarter. Hedge funds and other institutional investors own 78.99% of the company's stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.